Edition:
United States

Adverum Biotechnologies Inc (ADVM.A)

ADVM.A on American Stock Exchange

2.50USD
18 Aug 2017
Change (% chg)

$0.05 (+2.04%)
Prev Close
$2.45
Open
--
Day's High
$2.50
Day's Low
$2.50
Volume
0
Avg. Vol
--
52-wk High
$2.70
52-wk Low
$2.45

ADVM.A

Chart for ADVM.A

About

Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene... (more)

Overall

Beta: --
Market Cap(Mil.): $106.05
Shares Outstanding(Mil.): 43.29
Dividend: --
Yield (%): --

Financials

  ADVM.A Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -1.53 -- --
ROI: -28.12 2.83 14.89
ROE: -29.20 5.09 16.13

BRIEF-Adverum Biotechnologies files for mixed shelf of up to $150 mln

* Adverum Biotechnologies Inc files for mixed shelf of up to $150 million - ‍​sec filing Source text: (http://bit.ly/2wyLc11) Further company coverage:

Aug 10 2017

BRIEF-Adverum Biotechnologies Q2 loss per share $0.27

* Adverum Biotechnologies reports second quarter 2017 financial results and provides update

Aug 08 2017

BRIEF-Adverum Biotechnologies Q1 loss per share $0.38

* Adverum Biotechnologies reports first quarter 2017 financial results and provides update

May 09 2017

BRIEF-Adverum Biotechnologies on March 16, reached agreement in principle to settle consolidated securities class action lawsuit

* Adverum Biotechnologies- on March 16, reached agreement in principle to settle consolidated securities class action lawsuit

Mar 20 2017

BRIEF-Adverum Biotechnologies Q4 loss per share $0.54

* Adverum Biotechnologies reports fourth quarter and full year 2016 financial results and provides update

Mar 06 2017

Earnings vs. Estimates